Abstract
Gonadotropins secreting pituitary tumors tend to present as sellar mass with hypogonadism. Biologically active LH secretion by these tumors resulting in elevated testosterone is extremely rare. We report a case of a 48-year-old male patient who presented with giant pituitary tumor, elevated testosterone, and elevated levels of gonadotropins. Surgical resection of the tumor resulted in normalization of gonadotropins and fall in serum testosterone to subnormal levels in the postoperative period confirming that the tumor was secreting bioactive luteinizing hormone (LH).
1. Introduction
Most of the clinically nonfunctioning pituitary tumors are gonadotropin secreting tumors [1]. The initial manifestations of these gonadotroph tumors are visual defects, headache, and associated symptoms of anterior pituitary hormone deficiency [1]. Gonadotroph pituitary adenomas are inefficient producers and secretors of gonadotroph hormones: luteinizing hormone (LH), follicle-stimulating hormone (FSH), and the α-subunit of pituitary glycoprotein hormones [1]. Biologically active LH secretion by these tumors resulting in elevated testosterone is extremely rare. We report a case of a 48-year-old male patient who presented with giant pituitary tumor, elevated testosterone, and elevated levels of gonadotropins.
2. Case Summary
A 48-year-old man was referred for further management of a large pituitary tumor. His wife reported his having an increased libido for the preceding 12 months. Visual examination showed a mydriatic right pupil with a diminished light response and a right temporal field defect. There was no gynecomastia. Genital examination revealed testicular volumes approximating 25–30 cc. Biochemical evaluation showed an elevated total testosterone level of 1647 ng/dL (normal 220–1000; chemiluminescence immunoassay) and free testosterone of 515.1 pg/mL (normal 40–240; chemiluminescence immunoassay and ultrafiltration), with corresponding follicular-stimulating hormone (FSH) and LH levels of 32.7 mU/mL (normal 1–10) and 11.5 mU/mL (normal 1–7), respectively, consistent with a functional gonadotropinoma. There was no other hormonal cosecretion (Table 1). Magnetic resonance imaging (MRI) of the sella revealed a 4.5 × 3.3 × 2.5 cm sellar and suprasellar tumor, with optic nerve and chiasm compression and right cavernous sinus invasion (Figure 1). The patient underwent transsphenoidal surgery with dramatic reductions in postoperative total and free testosterone levels to 128 and 18.5, along with normalization of FSH and LH levels (6.0 mU/mL and 1.5 mU/mL), respectively. Postoperative MRI showed significant tumor debulking. Immunohistochemically, the adenoma (Figure 2(a)) stained positively for FSH (Figure 2(b)) but did not stain for LH (Figure 2(c)). Staining was repeated on different specimens of the tumor and the tumor consistently did not stain for LH. Slides prepared were not conducive for electron microscopy.
Table 1.
Test (normal range) | Preoperatively | Postoperatively |
---|---|---|
IGF-1 (52–328 ng/mL) | 64 | — |
Free thyroxine index (6–11 mcg/dL) | 3.8 | — |
ACTH (8–42 pg/mL) | 18 | 17 |
Basal cortisol | 9.8 | 20.4 |
Postsynacthen cortisol (normal > 18 mcg/dL) | 20.1 | — |
Prolactin (2–14 ng/mL) | 14 | — |
FSH (1–10 mIU/mL) | 32.7 | 6 |
LH (1–7 mIU/mL) | 11.5 | 1.5 |
Testosterone (total) (220–1000 ng/dL) | 1647 | 128 |
Testosterone (free) (40–240 pg/mL) | 515.1 | 18.5 |
17-β estradiol (<200 pg/mL) | 344 | 173 |
3. Discussion
Most gonadotropinomas are nonfunctional and clinically present as a pituitary macroadenoma and hypopituitarism [1, 2]. Immunostaining of these tumors is variable for FSH and/or LH, often unevenly distributed [3], and with the intensity of staining not correlated with plasma levels of gonadotropins [4]. There are multiple cases reported in the literature in which a functional FSH-secreting tumor results in spontaneous ovarian hyperstimulation syndrome [5–9] and of testicular enlargement [10–12]. Functional LH secreted by the tumor is extremely unusual and to our knowledge our case is the only fifth reported case in the literature [13–16]. The fact that the tumor did not immunostain using a specific monoclonal antibody against human LH, despite markedly elevated serum levels, suggests that the secreted LH was structurally different from human LH, with different epitopes detected only by the serum assay. Nonetheless, as evident from the elevated testosterone levels falling to low levels postoperatively, LH bioactivity was clearly retained. In vitro molecular analysis and electron microscopy of the tumor were not feasible with the samples available. Ultrasound of the scrotum to detect macroorchidism and serum inhibin levels was ordered to confirm the functionality of the FSH secreted; however, these results were not available at the time of publication.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
References
- 1.Snyder PJ. Extensive personal experience: gonadotroph adenomas. The Journal of Clinical Endocrinology and Metabolism. 1995;80(4):1059–1061. doi: 10.1210/jcem.80.4.7714066. [DOI] [PubMed] [Google Scholar]
- 2.Greenman Y, Stern N. Non-functioning pituitary adenomas. Best Practice and Research. 2009;23(5):625–638. doi: 10.1016/j.beem.2009.05.005. [DOI] [PubMed] [Google Scholar]
- 3.Salehi F, Vidal S, Horvath E, Kovacs K, Scheithauer BW. Tumors in the adenohypophysis. In: Lloyd RV, editor. Endocrine Pathology: Differential Diagnosis and Molecular Advances. Springer; 2010. pp. 73–83. [Google Scholar]
- 4.Young WF, Jr., Scheithaler BW, Kovacs KT, Horvath E, Davis DH, Randall RV. Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clinic Proceedings. 1996;71(7):649–656. doi: 10.1016/S0025-6196(11)63002-4. [DOI] [PubMed] [Google Scholar]
- 5.Baba T, Endo T, Kitajima Y, Kamiya H, Moriwaka O, Saito T. Spontaneous ovarian hyperstimulation syndrome and pituitary adenoma: incidental pregnancy triggers a catastrophic event. Fertility and Sterility. 2009;92(1):390.e1–390.e3. doi: 10.1016/j.fertnstert.2009.02.071. [DOI] [PubMed] [Google Scholar]
- 6.Cooper O, Geller JL, Melmed S. Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma. Nature Clinical Practice Endocrinology and Metabolism. 2008;4(4):234–238. doi: 10.1038/ncpendmet0758. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Roberts JE, Spandorfer S, Fasouliotis SJ, Lin K, Rosenwaks Z. Spontaneous ovarian hyperstimulation caused by a follicle-stimulating hormone-secreting pituitary adenoma. Fertility and Sterility. 2005;83(1):208–210. doi: 10.1016/j.fertnstert.2004.06.061. [DOI] [PubMed] [Google Scholar]
- 8.Murata Y, Ando H, Nagasaka T, et al. Clinical case seminar: successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma. Journal of Clinical Endocrinology and Metabolism. 2003;88(5):1988–1993. doi: 10.1210/jc.2002-021820. [DOI] [PubMed] [Google Scholar]
- 9.Karapanou O, Tzanela M, Tamouridis N, Tsagarakis S. Gonadotroph pituitary macroadenoma inducing ovarian hyperstimulation syndrome: successful response to octreotide therapy. Hormones. 2012;11(2):199–202. doi: 10.14310/horm.2002.1347. [DOI] [PubMed] [Google Scholar]
- 10.Heseltine D, White MC, Kendall-Taylor P, de Kretser DM, Kelly W. Testicular enlargement and elevated serum inhibin concentrations occur in patients with pituitary macroadenomas secreting follicle stimulating hormone. Clinical Endocrinology. 1989;31(4):411–423. doi: 10.1111/j.1365-2265.1989.tb01265.x. [DOI] [PubMed] [Google Scholar]
- 11.Clemente M, Caracseghi F, Gussinyer M, et al. Macroorchidism and panhypopituitarism: two different forms of presentation of FSH-secreting pituitary adenomas in adolescence. Hormone Research in Paediatrics. 2011;75(3):225–230. doi: 10.1159/000322211. [DOI] [PubMed] [Google Scholar]
- 12.Dahlqvist P, Koskinen LD, Brännström T, Hägg E. Testicular enlargement in a patient with a FSH-secreting pituitary adenoma. Endocrine. 2010;37(2):289–293. doi: 10.1007/s12020-009-9302-z. [DOI] [PubMed] [Google Scholar]
- 13.Klibanski A, Deutsch PJ, Jameson JL, et al. Luteinizing hormone-secreting pituitary tumor: biosynthetic characterization and clinical studies. The Journal of Clinical Endocrinology and Metabolism. 1987;64(3):536–542. doi: 10.1210/jcem-64-3-536. [DOI] [PubMed] [Google Scholar]
- 14.Chamoun R, Layfield L, Couldwell WT. Gonadotroph adenoma with secondary hypersecretion of testosterone. World Neurosurgery. 2012;80(6):900.e7–900.e11. doi: 10.1016/j.wneu.2012.11.069. [DOI] [PubMed] [Google Scholar]
- 15.Dizon MN, Vesely DL. Gonadotropin-secreting pituitary tumor associated with hypersecretion of testosterone and hypogonadism after hypophysectomy. Endocrine Practice. 2002;8(3):225–231. doi: 10.4158/EP.8.3.225. [DOI] [PubMed] [Google Scholar]
- 16.Ambrosi B, Bassetti M, Ferrario R, Medri G, Giannattasio G, Faglia G. Precocious puberty in a boy with a PRL-, LH- and FHS-secreting pituitary tumour: hormonal and immunocytochemical studies. Acta Endocrinologica. 1990;122(5):569–576. doi: 10.1530/acta.0.1220569. [DOI] [PubMed] [Google Scholar]